Indian equities are bracing for further declines as the Nifty 50 trades near 22,620, a level last seen in March. Continued heavy selling by foreign investors and elevated crude oil prices remain the key pressures. In this environment, investors are watching how companies like Blue Dart and Aurobindo Pharma navigate rising costs and changing market demand.
Indian stock markets are preparing for a weak opening on Thursday, October 1, 2026, as persistent foreign selling continues to weigh on investor sentiment. Benchmark indices, including the Nifty 50 and BSE Sensex, have been under pressure, with the Nifty closing at 22,620 on September 30. This level is a significant point of focus, as it marks the lowest close since March 30, 2026.
The selling pressure is primarily driven by foreign institutional investors, who have been aggressive sellers in recent sessions. Year-to-date, these outflows have exceeded $27 billion. This consistent withdrawal of capital is reducing liquidity in the market and keeping indices volatile. When foreign funds sell large volumes of shares, it often forces domestic markets to adjust to lower price levels until buyers find value.
Global macro factors are also contributing to the cautious mood. Brent crude oil prices are hovering around $98 per barrel. For India, which relies heavily on imported oil, high energy prices often mean higher costs for companies and potential pressure on consumer inflation. Additionally, U.S. Treasury yields remain elevated at approximately 5.29%. Higher bond yields in the U.S. often make emerging markets like India less attractive for global investors, who may prefer the safer, higher returns offered by U.S. government debt.
Amid these broad market struggles, some companies are making strategic moves to protect their bottom lines. Blue Dart Express has announced a price increase of 9% to 12% across its domestic service portfolio, effective January 1. This move is a direct response to rising operational expenses and is a common strategy companies use to maintain profit margins when input costs increase. Investors will watch whether this price hike affects customer demand or volume in the competitive logistics sector.
At the same time, Aurobindo Pharma is focusing on product diversification to drive growth. The company recently launched ADQUEY, a topical ointment for dermatitis, in the U.S. market. This highlights a trend where companies are trying to offset local economic challenges by entering or expanding in higher-value international markets. Expanding into specialized pharmaceutical products can help reduce reliance on generic drugs, which often face intense pricing pressure.
Technically, the Nifty 50 is testing the 22,600 support zone, which is close to its 200-week moving average. If the index fails to hold this level, it could lead to further selling toward the 22,400 zone. Investors will monitor whether domestic institutional buying can offset the foreign exodus, alongside tracking oil prices and any updates on U.S.-Iran geopolitical tensions, which remain a wildcard for global commodity prices.